Nature Reviews Drug Discovery, a monthly journal publishing high-quality, authoritative reviews on drug discovery and development, and Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, today announced a partnership that will combine the academic and intellectual expertise of Nature Publishing Group with the biotech and pharmaceutical market intelligence expertise of Decision Resources. The prototype report from this joint venture will be from Decision Resources' Pathways and Processes report series, and will be entitled Ion Channels: Emerging Therapeutic Opportunities.

"There is a great need for better dialogue between strategic planners within the pharmaceutical industry and academic scientists. The goal of the Nature Reviews Drug Discovery and Decision Resources partnership is to help these different communities to exchange ideas through a report that will integrate the complexity of the biology underlying drug discovery with an analysis of the current business environment," said Adam Smith, D.Phil., editor of Nature Reviews Drug Discovery. "By providing an in-depth view of how a variety of audiences are thinking about a biological pathway, the report will ensure that the pharma business leaders in the boardroom are on the same page as scientists in the laboratory."

The understanding of disease pathways and processes is central to the development of breakthrough therapies that are capable of treating multiple diseases and fundamentally changing clinical and medical practice. Ion Channels: Emerging Therapeutic Opportunities, due out at the end of the third quarter, will assess the potential of ion channel modulators for the treatment of a number of disease indications across several therapeutic areas, including cardiovascular disease, central nervous system diseases, and cancer. Decision Resources will provide an analysis of the competitive landscape and market opportunities in the disease indications, while Nature Reviews Drug Discovery will provide the views of leading authorities on a number of issues of fundamental importance to ion channel research.

"Decision Resources is excited to work with one of the world's leading drug discovery review journals in creating analysis that is important to the broad range of people within the pharmaceutical industry. The partnership between Nature Reviews Drug Discovery and Decision Resources will result in a report that is rich in science, technology, drug discovery implications, market ramifications, and competitive landscape analysis pertaining to specific cell-signaling pathways and cellular processes," said George Gaines, Ph.D., director of the Pathways and Processes and Infectious Diseases divisions at Decision Resources. "These reports bridge the gap in understanding between R&D professionals and market strategists."

About Ion Channels

Ion Channels: Emerging Therapeutic Opportunities is a Pathways and Processes report benefiting from the partnership between Decision Resources and Nature Reviews Drug Discovery. Published by Decision Resources, the Pathways and Processes series focuses on cellular and molecular pathways, providing insight into cutting-edge developments relating to drug targets with the potential to significantly change treatment practice and impact multiple pharmaceutical markets. By integrating focused interviews from leading academic experts with market analysis in multiple indications, Ion Channels: Emerging Therapeutic Opportunities will investigate the potential scientific and business opportunities of the next generation of targeted therapies.

About Nature Reviews Drug Discovery

Nature Reviews Drug Discovery is a monthly review journal that publishes authoritative, peer-reviewed articles by leaders in the field - providing a complete overview of the drug discovery and development arena, from disease mechanisms and chemistry, through to clinical development and regulatory issues. The journal, which integrates academia and industry, features cutting- edge review articles and highlights of the latest primary papers, as well as opinion articles and historical perspectives. For more information, visit www.nature.com/reviews/drugdisc.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:     Elizabeth Marshall            Clare Ellis    Decision Resources            Nature Reviews Drug Discovery    781-296-2563                  +44-(0)207-843-4592    emarshall@dresources.com      c.ellis@nature.com 

SOURCE: Decision Resources, Inc.,

CONTACT: Elizabeth Marshall for Decision Resources, +1-781-296-2563,
emarshall@dresources.com; or Clare Ellis for Nature Reviews Drug Discovery,
+44-(0)207-843-4592, c.ellis@nature.com

Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify to Garner 12% of the Schizophrenia Market in 2012

View Now